Josselyn
Mata Calidonio
a,
Arianna I.
Maddox
b and
Kimberly
Hamad-Schifferli
*ac
aDepartment of Engineering, University of Massachusetts Boston, Boston, MA, USA. E-mail: kim.hamad@umb.edu
bDepartment of Biology, University of Massachusetts Boston, Boston, MA, USA
cSchool for the Environment, University of Massachusetts Boston, Boston, MA, USA
First published on 18th July 2024
Rapid diagnostics are critical infectious disease tools that are designed to detect a known biomarker using antibodies specific to that biomarker. However, a way to detect unknown disease variants has not yet been achieved in a paper test format. We describe here a route to make an adaptable paper immunoassay that can detect an unknown biomarker, demonstrating it on SARS-CoV-2 variants. The immunoassay repurposes cross reactive antibodies raised against the alpha variant. Gold nanoparticles of two different colors conjugated to two different antibodies create a colorimetric signal, and machine learning of the resulting colorimetric pattern is used to train the assay to discriminate between variants of alpha and Omicron BA.5. By using principal component analysis, the colorimetric test patterns can pick up and discriminate an unknown variant that it has not encountered before, Omicron BA.1. The test has an accuracy of 100% and a potential calculated discriminatory power of 900. We show that it can be used adaptively and that it can be used to pick up emerging variants without the need to raise new antibodies.
As the infectious disease landscape is constantly evolving, it is urgent that we be ready for the next global pandemic. However, one challenge that has always remained is that we have never come up with a broadly accessible way to diagnose newly emerging infectious diseases.1 Viruses undergo continual mutations across various species, and zoonotic spillovers events, involving the transmission from animals to human, exert a substantial influence on the emergence of new outbreaks. An estimated 60–75% of all emerging human infectious diseases are thought to be zoonotic in origin.2 The heightened frequency of zoonotic spillover events is attributed to increasing levels of globalization, travel, urbanization, and shipping; these occurrences are further exacerbated by climate change, posing a persistent threat.3,4 Any given unknown pathogen might become the next big global pandemic if left unchecked, so the ability to rapidly identify unknowns circulating in the human population is of extreme importance. While complete identification in real time is impossible, information on what virus class it is, vector type (i.e., tick vs. mosquito borne), or what it is most similar to would be valuable in mounting a public health response to contain transmission, treat patients, and allocate resources.
Conventional LFAs require highly specific antibodies, but in order to produce them, the antigen target must first be identified before antibodies can be raised against it, thus preventing the ability to raise antibodies for an unknown. The only tool that can identify pathogens without prior knowledge of the target identity is DNA sequencing. However, sequencing is expensive, as it requires sophisticated equipment, reagents, and personnel, and is performed after PCR registers a positive. As a consequence, sequencing is commonly conducted in a centralized lab, with turnaround times spanning weeks or more. The COVID-19 pandemic spurred the opening of distributed sequencing centers that greatly enhanced the identification of new variants. However, these facilities were disproportionately concentrated in high-income countries, creating a significant disparity in genomic surveillance capabilities between high-income and low- to middle-income countries, primarily attributable to socioeconomic inequalities.5 Eventually, governments ultimately shuttered them because of high associated costs.6 Moreover, sequencing can still miss detection of the target if reference sequence or primers are not well suited to the divergent sequence, or the virus is present at low abundance, or the window in which the virus is present in the patient is short. Many infections by unknowns go undiagnosed. Therefore, we have a major flaw in our strategies to respond to newly emerging infectious diseases, and we urgently need to come up with a different tactic because the emergence of new diseases, strains, variants, and subtypes are now occurring with greater frequency. As it stands, diagnosing unknowns remains a major unmet need in global health.
However, chemists have determined a way to detect unknowns via olfactory arrays. To detect a range of previously unencountered analytes, they have developed novel sensors that act as a “chemical nose” or “chemical tongue”7,8 by employing a selective array rather than a specific binary (yes/no) sensor. In these cases, the signal is read out as a multidimensional pattern, or fingerprint, via principal component analysis (PCA).9 More importantly, chemical olfaction can classify these analytes that have never been encountered by the assay before.10 As selective arrays, they are not constrained to the detection of a limited number of target analytes, but instead can detect hundreds if not thousands of different species in pure form or in complex mixtures. Moreover, the format for olfaction sensors is highly versatile, with many ways to achieve readouts (e.g., electrochemical, fluorescence, colorimetric, nanoplasmonic, and others). It has been demonstrated to be powerful for a variety of analytes, ranging from small molecules, beverages,11 and disease cell types.12 Additionally, the sensor itself does not need to be expensive or difficult to operate, as they have been successfully implemented with colorimetric readouts on paper that can be imaged by a desktop scanner. The development of these sensors has given rise to overarching principles for constructing an olfactory array, where a salient feature is that it possesses some degree of cross-reactivity.13
Recognizing the power of chemical olfaction, we created a selective array in an immunoassay format to result in an adaptive diagnostic that can detect a biomarker that it has not encountered before. We chose to demonstrate it on variants of SARS-CoV-2 because the virus is a compelling model for a pathogen that evolves into new variants. COVID-19 disease evolution has occurred on an exceedingly accelerated timescale. In the last 4 years, we have been faced with more than 35 variants, with intervals between some variants spanning just a few weeks. (e.g., BA.1 and BA.5 in 2022).14,15 Each variant is effectively a new disease, where immunization or vaccination against one does not fully protect against future variants, and the nature of the disease has inflicted grave public health consequences and led to increasing disease burdens. The virus has mostly leveraged mutations on the receptor binding domain (RBD) in the spike protein (S) where it interacts with the angiotensin-converting enzyme 2 (ACE2) receptor on cells. However, nucleocapsid mutations have also been shown to be significant, contributing to increased infectivity, heightened transmission, and, notably, the ability to evade detection in rapid tests.16,17 While there are many available rapid tests that can diagnose SARS-CoV-2 infections, they cannot discriminate between variants.
The selective array also allowed us to leverage antibody cross-reactivity, as specificity is not required. By doing so, antibodies for another target can be repurposed.18 We utilized reagents that were available at a hypothetical time point of 2021–2022 after the alpha variant had emerged, and assumed we would have antibodies for alpha S RBD but not for what was newly emerging, Omicron BA.1 and Omicron BA.5 (timeline, Fig. 1). Starting with a pool of two antibodies from the alpha variant, we constructed a multicolor array and trained it with machine learning to detect the new variant BA.5 based on its colorimetric pattern. Then, using PCA, we show that the assay could pick up an unknown, BA.1, and classify it as something different from the previous variants it has encountered. We demonstrate that a limited set of just two cross-reactive antibodies can be repurposed to identify a newer variant if the array follows basic rules from chemical olfactory arrays. These results illustrate that rethinking how rapid paper tests are used can yield capabilities that go beyond yes/no answers. Furthermore, they show that strategic use of cross-reactive antibodies have the potential to pick up newly emerging pathogenic threats in a point of care format, ultimately aiding emergency preparedness.
![]() | ||
Fig. 1 a) Demonstrating a proof-of-concept assay that can detect a variant of SARS-CoV-2 that is previously unencountered by the assay. The assay uses only antibodies raised against alpha (Ab1 and Ab2), and is trained to detect BA.5 by its colorimetric fingerprint; b) the time window of the hypothetical test development (pink) is during the BA.1. and BA.5 outbreaks, and antibodies used are those raised against the earlier variant of alpha; c) phylogenetic tree of main SARS-CoV-2 variants. The scale bar indicates the genetic distance. From Wang et al.;19 d) sequence identity for the variants studied, with overlap in blue, and e) computed sequence identity (orange) and similarity (green) from BLASTp. |
From the biological reagents used, the antibodies for the spike receptor binding domain (RBD) were rabbit anti-spike IgG (Ab1) and human anti-spike IgG (Ab2), which were purchased from Sino Biological. Anti-mouse and anti-rabbit IgG antibodies (anti-Fc) for the control line were purchased from Sino Biological. The S RBDs used in the test pertained to the alpha, BA.1, and BA.5 variants, all from Sino Biological.
Red-colored gold NPs were synthesized according to established methods in the literature. Preceding the formation of the NP–Ab2 conjugate, 1 mL of red nanoparticles (NPs) underwent centrifugation at 6014g for 10 min to eliminate excess reagents. Following the removal of the supernatant, the NP pellet was reconstituted in a solution containing 140 mM HEPES (pH 7.48) and Ab2 (4.55 μg) and allowed to incubate on an orbital shaker for 60 min. A PEG backfilling step ensued, involving the addition of PEG-SH (1 × 10−9 mol), followed by a 10 min incubation on an orbital shaker. Subsequently, the NP–Ab2 complex underwent centrifugation at 3381g for 10 min and was then resuspended in 50 μL of 0.01 M PBS buffer.
Utilizing cuvettes with a 1 cm path length, optical absorption spectroscopy data were acquired on the spectramax molecular devices plate reader. The nanoparticle analyzer SZ-100 from HORIBA Scientific was employed to determine the hydrodynamic diameter (DH) of both the NPs and the NP conjugates.
We used microscale thermophoresis (MST) to characterize binding of each of the antibodies for each of the targets, alpha and BA.5 spike RBD proteins (Fig. 2a).28 The MST data was taken using the Monolith instrument and capillaries from NanoTemper. For each reading, ∼10 μL of our sample were added to the premium capillaries. The MST time traces for Ab1 incubated with alpha at different concentrations (Fig. 2b and inset, red) exhibited a systematic change with alpha concentration. The resulting dose response curve based on the MST traces exhibited an upward trend indicative of binding (Fig. 2c, pink), and a fit yielded a dissociation constant KD of 17.1 nM. When Ab1 was incubated with BA.5, the MST traces also exhibited a systematic change (Fig. 2b and inset, blue) and a dose response curve that suggested binding (Fig. 2c, blue) with a KD of 292.3 nM. Thus, Ab1 bound to both targets with reasonable affinity.
MST traces for Ab2 exhibited systematic concentration dependences for alpha (Fig. 2d, red) but not for BA.5 (Fig. 2d, blue). Ab2 dose response curves with alpha exhibited a concentration dependence that yielded KD = 22.8 nM (Fig. 2e, pink), but did not change significantly with BA.5 concentration, and yielded a KD = 12.7 nM (Fig. 2e, blue). Thus, Ab2 bound with different affinities for alpha vs. BA.5. We note that thermophoretic trends for Ab2 binding to the antigens were the opposite direction from Ab1, which can occur in MST due to differences in the thermophoretic properties of the bound complex relative to the free species.29,30 Overall, the MST results showed that the two anti-alpha antibodies exhibit differential binding for each of the targets, and thus the set had potential to be used as a selective array.
Gold NPs were synthesized using an aqueous approach using citrate reduction which resulted in ∼30 nm diameter spherical particles that were red in color.31 NPs were conjugated to each of the antibodies by incubation in solution, which allows them to bind to the NP surface by physisorption. While there are conjugation strategies that utilize covalent click chemistry, those tend to result in lower reaction yield, and others have found that physisorption does not compromise the ability of the antibody to bind to a target.32
We then ran every possible antibody pair with each antigen plus no antigen as the negative control (Fig. 3a). Each antibody (Ab1, Ab2) was immobilized on a nitrocellulose strip at the test area. The control antibody (anti-Fc) was immobilized on the control line as a positive control to verify flow. Then, the strip was run with a given NP–Ab conjugate with each of the targets. Given two antibodies which could be either immobilized antibodies or conjugated on the NPs as immunoprobes, this resulted in 2 immobilized antibodies × 2 immunoprobes × 3 antigen cases (alpha, BA.5, negative control) = 12 different strips. Fig. 3b shows test strip images for the pair consisting of immobilized Ab1 and NP–Ab1. The test area intensity varied depending on which antigen was run, with a strong intensity for S RBD from alpha, and a much lower intensity for BA.5. No signal was observed at the test area when no antigen was present (control). RGB intensities of the test areas were quantified by ImageJ25 and plotted as a heat map for the different immobilized antibodies (horizontal) vs. NP–antibody conjugates (vertical) (Fig. 3c). A range of cross reactivities with the antibody pairs was observed. For example, immobilized Ab1 run with NP–Ab1 resulted in a finite signal for BA.5 (14.42 RGB intensity), but when run with NP–Ab2 exhibited nearly no signal (0.55 RGB intensity). On the other hand, all pairs demonstrated signal when run with alpha. Negative controls showed a range of baseline signal below 10 RGB, which could be attributed to non-specific adsorption. This shows that depending on the antibody pair, the antigens produce different signal intensities, illustrating that this set of antibodies had the potential to discriminate between the variants.
We designed the assay based on how the antibodies paired with each of the antigens (Fig. 3). The multiplexed assay had two test areas with Ab1 and Ab2 immobilized at different locations, and was run with a mixture of blue GNS–Ab1 and red NP–Ab2 so the test areas could yield a range of colors (Fig. 4). Thus, a different colorimetric pattern resulted based on the antigen that was run.
To complement the red NPs, we synthesized star-shaped gold nanoparticles, or gold nanostars (GNS) which were blue in color (Fig. 4c). GNS were synthesized using a reduction of a Goods buffer21 so that their peak SPR was at 708 nm (Fig. 4a, blue line) which was shifted considerably from the SPR of the spherical red NPs (Fig. 4a, red line). DLS showed that the GNS had an average DH of 215.4 ± 44.7 nm. When the NP and GNS antibody conjugates were spotted down on nitrocellulose, the format of the final assay (Fig. 4f), their colors were visually distinguishable.34
Ab1 was conjugated to the blue GNS and Ab2 was conjugated to the red NPs. DLS showed that the GNS exhibited an increase in DH of from 215.4 nm to 246 nm for the GNS–Ab1, and the NPs from 33.6 nm to 56.4 nm for the NP–Ab2 (Fig. 4b), confirming successful conjugation. UV-vis showed a slight peak shift but no major decrease in intensity, thus exhibiting no significant aggregation (Fig. 4a, dotted lines). This also confirmed conjugation to the antibodies and that they were stable in solution.
The training model chosen for the training of the test was linear discriminant analysis (LDA). LDA analyses were performed based on the deconvoluted RGB values of the test spots. LDA is advantageous when dealing with multivariate data, such as deconvoluted RGB values of two spots, as it maximizes the separation between class means while minimizing within-class variability. For test optimization, a 5-fold cross-validation was performed, which involves the partitioning of the dataset into subsets, training the model on a subset, and validating its performance on the remaining data. By validating the model on different subsets, cross-validation provides a more robust evaluation of its performance, enhancing the reliability of the LDA analysis on the deconvoluted RGB values of the test spots.
A confusion matrix was used to evaluate the accuracy of the resulting test based on the LDA model, where on-diagonals in the confusion matrix indicated correctly classified results (predicted class = true class) and off diagonals indicated incorrectly classified ones (predicted classes19 true class). Initial conditions resulted in an accuracy of 22.22%. Changing running conditions (washes, buffers, quenching agents) could improve accuracy to 55.56%, 66.67% (ESI† Fig. S2), and then ultimately 100% (Fig. 4h). Using the finalized as the optimal running conditions, if alpha was run, it resulted in signal at both test areas, where the lower area was bluer and the upper one more purple. If BA.5 was run, it resulted in only one spot on the upper test location which was blue in color (Fig. 4e). This shows that the resulting test pattern could discriminate between variants and thus was successfully optimized.
LDA of the top two components showed data clusters based on the variant run (Fig. 4g, ellipses indicating 95% confidence). The cluster for alpha was well separated from both BA.5 and the negative control, with no overlap. This shows that the assay could successfully discriminate between alpha and BA.5 variants using entirely repurposed alpha antibodies without the need for specific antibodies against BA.5. This shows the potential for discriminating SARS-CoV-2 variants in a rapid test format, which to date have not allowed variant identification, and that it can be achieved without antibodies specific for that variant.
![]() | ||
Fig. 5 a) Challenging the test with an unknown variant. Strips were run with alpha, BA.5, and then challenged with BA.1 as a new variant; b) resulting strip images run with the unknowns; c) PCA of clustering with 95% confidence ellipses, with unknowns in green and BA.1 unknown in orange triangles; d) dendrogram constructed using HCA; e) RGB plot of test areas showing the range of colors possible for the GNS–Ab1 (blue prism) and NP–Ab2 (pink prism). Each individual dot is the RGB value for a given test result and/or spotted strip (ESI† Fig. S5); f) scree plot of the assay. |
Strips run with BA.1 exhibited a different colorimetric pattern compared to alpha, BA.5, and the negative control, where it resulted in a single dark blue spot at the upper test area (Fig. 5b, triplicates, ESI† Fig. S5). To determine whether this pattern was distinguishable from those of the other targets, we used PCA of the stain vectors of the RGB values of the two test areas. BA.1 clustered in an entirely new region that was well separated from alpha, BA.5, and the negative control, with no overlap (Fig. 5c, orange). Thus, the colorimetric pattern was sufficiently distinct to enable discrimination of BA.1 from alpha and BA.5. This shows that the test could identify a new variant on which it was not trained.
The other unknowns were species the assay had encountered before (negative control, alpha, and BA.5) which were also correctly classified, where each of them was properly assigned to their respective clusters (Fig. 5c, green triangles). A zoom in of the data in 3D is shown in ESI,† Fig. S6.
Dendrograms were constructed using hierarchical cluster analysis (HCA) of the RGB data (Fig. 5d).11 Unknowns (bold, marked with *) were located within the clusters of their true classes. Thus, the test correctly classified the unknown variants. This shows that the assay using only antibodies for alpha, could pick up an unknown variant on which it was not trained, and distinguish it from the variants in the original training set.
The 24-spot olfactory array of Suslick et al. could discriminate between a massively large number of analytes.39 In this context, the discriminatory power refers to the ability of the array to distinguish between different analytes based on the unique colorimetric patterns produced by the interaction of the compounds with the array of chemo-responsive dyes. Assuming detectable RGB 8-bit differences of 4 and utilizing their scree plot, they estimated a discriminatory power of 1012.39 To calculate the discriminatory power of our assay, we quantified the number of distinct patterns the multiplexed immunoassay can generate, which is determined by the variability and resolution of the color changes observed, number of test areas available, and the distribution of the variance within the data. Here, the red NPs and blue GNS do not span the entire RGB spectrum, especially when they are spotted onto paper substrates, and thus are expected to yield a narrower range of possible RGB values. To determine the range of possible colors at a test strip, we experimentally measured the RGB values for different concentrations of the red NP–Ab2 and blue GNS–Ab1 on nitrocellulose. We spotted the GNS–Ab1 and NP–Ab2 down on nitrocellulose in aliquots up to the final volume used in an assay run (3 μL for blue GNS–Ab1, 2 μL for red NP–Ab2, ESI† Fig. S7) and measured RGB values of the spots (Fig. 5e). Given that the entire RGB space is not accessible with these two stains, we experimentally determined the number of distinct colors achievable by mixing the NP and GNS at various ratios. Included in the figure are the RGB values for mixtures of red NP–Ab2 and blue GNS–Ab1 spotted down on nitrocellulose as well as all of the RGB values of test areas from the strips for the negative control, alpha, BA.5, and BA.1. The maximum RGB value for each immunoprobe is indicated (blue and pink prisms). Based on the available RGB space, we estimated that there are ∼30 distinguishable colors for a given spot, so for two spots this yields (30)2 = 900 possible combinations. While 8-bit RGB analysis theoretically allows for finer color distinctions, we opted for a more conservative estimate to avoid overstating the assay's discriminatory power. Based on the scree plot showing the cumulative percentage of the variance as a function of the principal components (Fig. 5f), we found that >99% of the information is contained within two components, so that only 2 components are necessary for discriminating the analytes. While this is a rough estimate for the discriminatory power, it is still higher compared to the total number of confirmed SARS-CoV-2 variants, which is currently over 35.40,41
Chemical olfactory arrays can discriminate a large number of closely related species by using a large array of binding agents which possess a range of cross reactivities, where some species will bind broadly to all analytes, and others to only a select few. They typically rely on a single binding event between the analyte and the immobilized sensor molecule to induce a color change, typically employing porphyrins and other organometallic molecules.11,39 However, for paper immunoassays, a signal is generated upon sandwich formation of the antigen with both with NP–Ab and the immobilized Ab. Because there are two binding events, the signal is the result of two different binding affinities. This affords room for differential signals in our 2-spot array, which has only 12 different possible combinations for sandwich formation. Based on the estimated discriminatory power, we believe that an extensive array of antibodies is not necessary in order to discriminate between several variants. Thus, the test can be quite economical, as antibodies are the most expensive component in a lateral flow assay strip.24 Furthermore, using polyclonals for certain antibodies is advantageous, as they can bind to a range of epitopes on the target. Consequently, they have a higher probability of cross-reactivity, a favorable attribute for adaptive immunoassays. While the benefit of monoclonals is attractive due to their high specificity, this actually can be a drawback when trying to make an adaptive assay that can detect an emerging target, and they would need to be combined with the use of polyclonals. Here, because Ab1 and Ab2 are polyclonal, we showed that they exhibited different levels of cross-reactivity sufficient to make an array. Ultimately, determining the number of suitable test areas with unique antibodies and also NP–Ab conjugates is something that requires systematic experimental investigation, where the antibodies are varied and the ability to distinguish unknowns is quantified, and will be subject of future studies.
This assay was exclusively built using antibodies raised against the alpha variant, eliminating the necessity for antibodies tailored to each detectable variant. This underscores the ability to repurpose reagents successfully. Furthermore, the assay required only two different antibodies—one that was cross reactive, and one that was less so. Commercial antibodies were deliberately chosen to show that custom antibodies are not required.
While we have demonstrated repurposing antibodies in immunoassays before, here we applied the technique to the SARS-CoV-2 spike protein for variant discrimination. Previously, our studies demonstrated the adaptability of repurposing antibodies from one virus to effectively detect an entirely different virus, e.g., repurposing dengue and Zika antibodies to detect yellow fever NS1, or utilizing dengue antibodies for Zika detection, and even repurposing dengue 3 antibodies to detect dengue serotypes 1–4. Notably, in all of these instances, the targets were already identified, where the test was trained on the targets via supervised learning. In addition, the sequence similarities in the prior works were comparatively lower, approximately ∼55%, ∼75%, and ∼85%, respectively.18,33 Variants of SARS-CoV-2 are more challenging because sequence identity and similarity between them are much higher in comparison (>95%). Taking into consideration these prior examples, this shows that repurposing antibodies can be successful with a large range of sequence similarities. Future work could push the upper and lower bounds on similarities as well as epitope mapping to gain a fuller understanding of the mechanism, and then extend this approach to pick up an unknown disease.
Current approaches in diagnostic development have significant shortcomings, with major bottlenecks in antibody production,42–44 where deployment of a point of care LFA test can take as long as a year. This is far too long to aid in rapid response to new diseases, which are often characterized by large increases in cases within a timeframe of weeks. This problem highlights the need for new ways outside of traditional approaches to get diagnostics for emerging diseases on the ground sooner.45 Ignoring new outbreaks or not scanning for potential ones has dangerous consequences.46 Past experience has shown that public health systems need to be better prepared not just for the next SARS-CoV-2 variant, but for the next virus, pointing to the dire need for widespread disease surveillance.47 While there are surveillance efforts sequencing viruses in animal populations that can potentially induce zoonotic spillover, these spillover events are rare, making it nearly impossible to predict what will cause the next pandemic.48,49 Arguably, our response to new outbreaks has been suboptimal, primarily attributed to our inadequate preparedness for such events.50 This underscores the fact that traditional approaches, i.e., generating a new antibody for every new disease variant once we detect it in circulation, are not rapid enough for an effective response.
The approach here can offer a solution to detect an unknown and classify it in a rapid, widely deployable format. It has the potential to be applied to other pathogens and evolving targets, not just viral but also bacterial targets.1 While it is probably not possible to make a single universal immunoassay that can detect any virus, it seems plausible to make for a broad virus type (e.g., one that encompasses flaviviruses, another for coronaviruses, filoviruses, etc.). Furthermore, the assay can be tailored to target things that could potentially arise in a particular geographic region. It should be of note that the identity of the antibodies used in the assay may result in limitations in their range of cross reactivities and what the ultimate assay can detect and distinguish. Also, traditional challenges faced by paper immunoassays such as non-specific adsorption and sample matrix effects would still be a potential problem.
The protocol is simple to execute and results in a low-cost assay, as it uses colorimetric/visual sensing, where readout does not require sophisticated instrumentation and can be via mobile phone images or desktop scanners. Moreover, the protocol can be easily shared and adapted to whatever reagents an end-user has, eliminating the need for specialized reagents and antibodies that may not be currently accessible. This renders it amenable for wide distribution, unlike sequencing which has intensive requirements for trained personnel, instrumentation, reagents, energy, and lab infrastructure. Additionally, the affinity agents in the immunoassay are not limited exclusively to antibodies; they may encompass peptides, nanobodies, or other species that have reasonable (∼nM) binding affinity.
The machine learning (ML) script was used in ref. 35 (Mata Calidonio and Hamad-Schifferli) and is available in the ESI† for that publication.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4lc00505h |
This journal is © The Royal Society of Chemistry 2024 |